Hepatit C Virus Enfeksiyonlu Hastalarda Pegile İnterferon-Ribavirin Tedavisi Yanıtı ile Kemokin Ligand ve Reseptör Düzeyleri İlişkisi
Articles > Article · 2017
Authors: Orçun ZORBOZAN, İlknur KALELİ, Hüseyin TURGUT
TÜRK MİKROBİYOLOJİ CEMİYETİ DERGİSİ, Other Refereed National Journals, National, 2017, vol 47, pp 11-20
Summary
<p style="text-align: justify;"><span style="font-size:12px"><span style="font-family:arial,helvetica,sans-serif"><span style="color:rgb(17, 17, 17)"><strong>Objective:</strong> Antiviral agents used in chronic HCV infection treatment have serious side effects. HCV-RNA is used to evaluate treatment response. HCV genotype is used for determining duration and dose of treatment but there is no definite predictor of treatment response yet. This study is designed to investigate the relationship between chemokines, chemokine receptors, delta-32 deletion and HCV infection treatment response.</span></span></span></p> <p style="text-align: justify;"><span style="font-size:12px"><span style="font-family:arial,helvetica,sans-serif"><span style="color:rgb(17, 17, 17)"><strong>Material and Methods: </strong>Fifty chronic HCV-infected patients and 28 healthy controls were included in the study . Serum CCL3, CCL4, CCL5, CXCL9 and CXCL10 levels were measured by commercial ELISA kits. CCR5 and CXCR3 surface expressions of peripheral blood CD8+ cells were evaluated by flow-cytometry. Delta-32 deletions were evaluated by real-time PCR.</span></span></span></p> <p style="text-align: justify;"><span style="font-size:12px"><span style="font-family:arial,helvetica,sans-serif"><span style="color:rgb(17, 17, 17)"><strong>Results: </strong>Patients were divided into two groups according to their treatment responses. In both of the patient groups, percentages of CCR5+-CD8+ lymphocytes and CXCR3+- CD8+ lymphocytes were higher than those of the control (p=0.001, p=0.021, respectively); but there was no significant difference between patient groups (p=0.872). CCL3, CXCL9 and CXCL10 levels were significantly higher in patient groups than those of the control. CCL4 and CCL5 levels were not significantly different among responders, non-responders and contro subjectsl. CCL3, CCL4, CCL5 and CXCL9 levels were not significantly different between responder and non- responder patients, while CXCL10 levels in non-responders were higher than those of responders (p=0.001).</span></span></span></p> <p style="text-align: justify;"><span style="font-size:12px"><span style="font-family:arial,helvetica,sans-serif"><span style="color:rgb(17, 17, 17)"><strong>Conclusion:</strong> According to the findings of this study, CCR5 and CXCR3 surface expressions of CD8+ cells in the peripheral blood increased in chronic hepatitis C but there was no difference between responder and non-responder patient groups; CCL3, CXCL9 and CXCL10 levels increased in HCV infection, however, only CXCL10 predicted the treatment response. Keywords: Delta 32, chemokines, host-virus interactions</span></span></span></p>